Steven Kaminsky | Chief Science Officer
International Rett Syndrome Foundation

Steven Kaminsky, Chief Science Officer, International Rett Syndrome Foundation

Dr. Kaminsky joined the International Rett Syndrome Foundation in January of 2012. He came to the Foundation after serving 11 years as the Vice President of Research for the Uniformed Services of the Health Sciences, the Department of Defense Medical School serving all the uniformed services of the United States.. Originally from Binghamton, NY, he holds a Bachelor of Science Degree from Hobart College, Geneva, NY. He received a Master’s of Science Degree in biology from Northern Michigan University and his Doctor of Philosophy in Pathology from the State University of New York at Buffalo. During his doctoral work at Buffalo, Dr. Kaminsky received two national awards; the Mead Johnson Award for Excellence in Research and the James A. McLaughlin Award for research in infectious disease. Dr. Kaminsky did his postdoctoral fellowship at the Cancer Center of the Strong Memorial Hospital at the University of Rochester. At Strong Memorial Hospital he investigated the role of oncogenes in normal development. In 1985 Dr. Kaminsky was appointed to the rank of Assistant Professor in the Department of Pathology at the University of Buffalo where he studied the genetics of bone marrow transplantation. In 1991 Dr. Kaminsky joined the National Institutes of Health as the Program Officer of the Developmental Genetics Program at the National Institute of Child Health and Human Development. At NICHD he worked on many trans-NIH projects and received an NIH Merit Award for his efforts. In 1995 Dr. Kaminsky was invited to the Baylor College of Medicine as the Vice Chairman of the Department of Molecular and Human Genetics at the Baylor College of Medicine. At Baylor he was part of the team that built the Department into one of the largest Genetics Program in the United States.


World Orphan Drug Congress USA 2018 - Conference Day One @ 11:25

Empowered educated patients influencing pre-clinical development and working with industry to optimize drug discovery

  • Patient groups role guiding research, disease understanding, supporting pre-clinical development and follow up experiments 
  • Driving translational research and the influence on formulation, routes to delivery and overall clinical development 
  • Effective partnerships between advocacy and industry to expand collaborations that can support enrollment and physician engagement

back to speakers